Despite the advances in treating multiple myeloma, some patients relapse early even when given the latest triplet and quadruplet combination therapies and maintenance following a stem cell transplant. At the International Myeloma Society 21st Annual Meeting & Exposition Thursday, experts […]
Reaching Consensus on Defining, Treating High-Risk Myeloma Read More »
It’s been almost 50 years since “monoclonal gammopathy of undetermined significance,” or MGUS, was identified as a precursor to multiple myeloma. Yet the debate over when and how to treat patients who have not developed the organ damage associated with
Risk Factors, Who to Treat, How to Treat Read More »
More than 20 years after the first papers on the topic appeared, use of minimal residual disease (MRD) negativity is poised to become a common surrogate end point in accelerated approvals for therapies for multiple myeloma and perhaps for other
After ODAC, What’s Next for MRD Testing in Multiple Myeloma? Read More »
